Şeyma Özden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Şeyma Özden has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Merve Tepetam
Clinic of Immunology and Allergy, University of Health Sciences, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye
15 shared publications - Cihan Orcen
Clinic of Allergy and Immunology, University of Health Sciences, Kocaeli Derince Training and Research Hospital
8 shared publications - Tugce Yakut
University of Health Sciences, Diyarbakır Gazi Yasargil Training and Research Hospital, Diyarbakır, Turkey
8 shared publications - Ali Can
Clinic of Immunology and Allergy, University of Health Sciences Van Training and Research Hospital, Van, Türkiye
6 shared publications - Bilun Gemicioglu
Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Türkiye
6 shared publications - Dilsad Mungan
Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine
6 shared publications
Latest Publications
- 2 October 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (3) , 191-194
Hidden granulomatous-lymphocytic interstitial lung disease (GLILD): A missed diagnosis in granulomatous and interstitial lung diseases
- 2 October 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (3) , 191-194
Hidden granulomatous-lymphocytic interstitial lung disease (GLILD): A missed diagnosis in granulomatous and interstitial lung diseases
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 74-80
Serum EDN as a novel biomarker for severe eosinophilic adult asthma
Background: Eosinophilic inflammation is a major pathophysiological mechanism in severe asthma (SA). However, a reliable serum biomarker reflecting this type of inflammation has not yet been identified. Therefore, in this study, we aimed to investigate whether serum levels of eosinophil-derived neurotoxin (EDN) could serve as a biomarker for predicting the diagnosis of SA in adult patients with asthma. Methods: A total of 89 patients, including 52 with SA and 37 with nonsevere asthma (NSA), were included in the study, all having PBEC ≥ 150 cells/µL. The relationships between serum EDN and serum eosinophilic cationic protein (ECP) levels with peripheral blood eosinophil count (PBEC), as well as with clinical and demographic parameters, were assessed. In addition, the clinical validity of serum EDN and PBEC levels in predicting the SA phenotype was evaluated. Results: A correlation analysis among PBEC, serum EDN, and serum ECP levels revealed statistically significant positive correlations: between PBEC and serum ECP (p<0.001), PBEC and serum EDN (p<0.001), and serum ECP and serum EDN (p=0.002). Serum EDN and PBEC levels were significantly higher in the SA group compared to the NSA group (225.40 [0.001–588.76] vs. 380.05 [0.001–1920.45], p<0.001; 290 [160–820] vs. 335 [170–2070], p=0.003, respectively). Regarding spirometric parameters, FEV1 (mL and %), FVC (mL and %), and FEF25–75 (mL and %) values were significantly lower in the SA group compared to the NSA group. In the receiver operating characteristic (ROC) curve analysis evaluating the predictive value of serum EDN levels for identifying the SA phenotype, a sensitivity of 69% was observed. In univariate analysis, both serum EDN and PBEC levels were significantly associated with SA. However, multivariate analysis demonstrated that only serum EDN levels remained a statistically significant independent predictor of the SA phenotype. Conclusions: Serum EDN emerged as an independent predictor of the SA phenotype and demonstrated superior diagnostic performance compared with conventional eosinophilic markers. These findings highlight its potential as a promising biomarker for identifying SA and reflecting underlying type 2 airway inflammation.
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 74-80
Serum EDN as a novel biomarker for severe eosinophilic adult asthma
Background: Eosinophilic inflammation is a major pathophysiological mechanism in severe asthma (SA). However, a reliable serum biomarker reflecting this type of inflammation has not yet been identified. Therefore, in this study, we aimed to investigate whether serum levels of eosinophil-derived neurotoxin (EDN) could serve as a biomarker for predicting the diagnosis of SA in adult patients with asthma. Methods: A total of 89 patients, including 52 with SA and 37 with nonsevere asthma (NSA), were included in the study, all having PBEC ≥ 150 cells/µL. The relationships between serum EDN and serum eosinophilic cationic protein (ECP) levels with peripheral blood eosinophil count (PBEC), as well as with clinical and demographic parameters, were assessed. In addition, the clinical validity of serum EDN and PBEC levels in predicting the SA phenotype was evaluated. Results: A correlation analysis among PBEC, serum EDN, and serum ECP levels revealed statistically significant positive correlations: between PBEC and serum ECP (p<0.001), PBEC and serum EDN (p<0.001), and serum ECP and serum EDN (p=0.002). Serum EDN and PBEC levels were significantly higher in the SA group compared to the NSA group (225.40 [0.001–588.76] vs. 380.05 [0.001–1920.45], p<0.001; 290 [160–820] vs. 335 [170–2070], p=0.003, respectively). Regarding spirometric parameters, FEV1 (mL and %), FVC (mL and %), and FEF25–75 (mL and %) values were significantly lower in the SA group compared to the NSA group. In the receiver operating characteristic (ROC) curve analysis evaluating the predictive value of serum EDN levels for identifying the SA phenotype, a sensitivity of 69% was observed. In univariate analysis, both serum EDN and PBEC levels were significantly associated with SA. However, multivariate analysis demonstrated that only serum EDN levels remained a statistically significant independent predictor of the SA phenotype. Conclusions: Serum EDN emerged as an independent predictor of the SA phenotype and demonstrated superior diagnostic performance compared with conventional eosinophilic markers. These findings highlight its potential as a promising biomarker for identifying SA and reflecting underlying type 2 airway inflammation.
- 25 March 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (1) , 71-73
Successful and practical pirfenidone desensitization
- 25 March 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (1) , 71-73
Successful and practical pirfenidone desensitization
- Open Access
- 1 March 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (2) , 117-124
Stepwise, precision-based management of allergic Bronchopulmonary Aspergillosis/Mycosis: A real-life multicenter study
Background: Allergic bronchopulmonary aspergillosis (ABPA) and allergic bronchopulmonary mycosis (ABPM) are hypersensitivity disorders characterized by fungal colonization of the airways and exaggerated Th2-mediated immune responses. Despite corticosteroids being the cornerstone of treatment, adverse effects, relapses, and steroid dependence necessitate adjunctive antifungal and biologic therapies. This study aimed to evaluate clinical, functional, and immunologic responses to different treatment combinations in patients with ABPA or ABPM. Methods: This retrospective, multicenter, cross-sectional study included 70 patients diagnosed with ABPA (n = 54) or ABPM (n = 16) at two tertiary chest disease centers between 2016 and 2023. Patients were grouped according to systemic corticosteroid (SS) use (SS-using vs non-SS) and further subdivided based on treatment composition (antifungal ± biologic therapy vs antifungal alone). Changes in FEV1 (Forced Expiratory Volume in 1 second), Asthma Control Test (ACT) scores, total serum IgE, and peripheral blood eosinophil count (PBEC) before and after treatment were analyzed. Results: In the SS-using group, combination therapy with antifungal ± biologic agents produced significant improvements in FEV1 (mL and %) and ACT scores, along with substantial reductions in total IgE and PBEC levels (all P < 0.05). Antifungal monotherapy yielded significant reductions in immunologic parameters but no functional improvement. In the non-SS group, changes were minimal across most parameters, except for a modest reduction in total IgE within the antifungal ± biologic subgroup. The most comprehensive clinical and immunologic responses were observed in patients treated with corticosteroids combined with antifungal and biologic therapy. Conclusion: SS remain the primary therapeutic modality for ABPA, but the addition of antifungal and biologic agents enhances both immunologic and functional recovery. A precision-based, stepwise treatment model—initiating with corticosteroids, followed by antifungal therapy, and incorporating targeted biologics—may optimize long-term outcomes, minimize steroid exposure, and promote sustained remission in ABPA and ABPM.
- 1 March 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (2) , 117-124
Open AccessStepwise, precision-based management of allergic Bronchopulmonary Aspergillosis/Mycosis: A real-life multicenter study
Background: Allergic bronchopulmonary aspergillosis (ABPA) and allergic bronchopulmonary mycosis (ABPM) are hypersensitivity disorders characterized by fungal colonization of the airways and exaggerated Th2-mediated immune responses. Despite corticosteroids being the cornerstone of treatment, adverse effects, relapses, and steroid dependence necessitate adjunctive antifungal and biologic therapies. This study aimed to evaluate clinical, functional, and immunologic responses to different treatment combinations in patients with ABPA or ABPM. Methods: This retrospective, multicenter, cross-sectional study included 70 patients diagnosed with ABPA (n = 54) or ABPM (n = 16) at two tertiary chest disease centers between 2016 and 2023. Patients were grouped according to systemic corticosteroid (SS) use (SS-using vs non-SS) and further subdivided based on treatment composition (antifungal ± biologic therapy vs antifungal alone). Changes in FEV1 (Forced Expiratory Volume in 1 second), Asthma Control Test (ACT) scores, total serum IgE, and peripheral blood eosinophil count (PBEC) before and after treatment were analyzed. Results: In the SS-using group, combination therapy with antifungal ± biologic agents produced significant improvements in FEV1 (mL and %) and ACT scores, along with substantial reductions in total IgE and PBEC levels (all P < 0.05). Antifungal monotherapy yielded significant reductions in immunologic parameters but no functional improvement. In the non-SS group, changes were minimal across most parameters, except for a modest reduction in total IgE within the antifungal ± biologic subgroup. The most comprehensive clinical and immunologic responses were observed in patients treated with corticosteroids combined with antifungal and biologic therapy. Conclusion: SS remain the primary therapeutic modality for ABPA, but the addition of antifungal and biologic agents enhances both immunologic and functional recovery. A precision-based, stepwise treatment model—initiating with corticosteroids, followed by antifungal therapy, and incorporating targeted biologics—may optimize long-term outcomes, minimize steroid exposure, and promote sustained remission in ABPA and ABPM.
- Open Access
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 154-159
Beyond atopy: etiological evaluation of markedly elevated serum total IgE (>1000 IU/ml)
Aims: Marked elevation of serum total immunoglobulin E (IgE) levels (>1000 IU/ml) is most commonly associated with atopic diseases; however, its underlying etiology is highly heterogeneous. This study aimed to systematically evaluate the etiological factors associated with markedly elevated serum total IgE levels in patients attending an allergy and immunology outpatient clinic. Methods: Medical records of 1103 patients with serum total IgE levels >1000 IU/ml who presented to the allergy and immunology outpatient clinic between January 1 and September 1, 2023, were retrospectively reviewed. Patients with only a single outpatient visit and those who did not undergo adequate diagnostic evaluation to determine the cause of IgE elevation were excluded. A total of 643 patients who completed comprehensive clinical, laboratory, and diagnostic assessments were included in the final analysis. Etiological causes of IgE elevation were classified based on clinical and laboratory findings. Results: The mean age of the 643 patients was 47.55±17.00 years, and 52.9% were female. The median serum total IgE level was 1520 (1001–62,753) IU/ml. Atopic diseases were identified as the most common etiological factor (n:530, 82.4%). Other causes included infectious diseases (5.3%), inflammatory diseases (1.2%), neoplasms (0.5%), primary immunodeficiency disorders (0.2%), drug-related causes (0.2%), and other conditions (0.2%). Despite comprehensive evaluation, no underlying cause could be identified in 65 patients (10.1%), who were classified as having idiopathic total IgE elevation. Conclusion: Although markedly elevated serum total IgE levels are predominantly associated with atopic diseases, a substantial proportion of patients have alternative or unidentified etiologies. A systematic and multidisciplinary diagnostic approach is essential to accurately identify the underlying cause of IgE elevation and to guide appropriate clinical management.
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 154-159
Open AccessBeyond atopy: etiological evaluation of markedly elevated serum total IgE (>1000 IU/ml)
Aims: Marked elevation of serum total immunoglobulin E (IgE) levels (>1000 IU/ml) is most commonly associated with atopic diseases; however, its underlying etiology is highly heterogeneous. This study aimed to systematically evaluate the etiological factors associated with markedly elevated serum total IgE levels in patients attending an allergy and immunology outpatient clinic. Methods: Medical records of 1103 patients with serum total IgE levels >1000 IU/ml who presented to the allergy and immunology outpatient clinic between January 1 and September 1, 2023, were retrospectively reviewed. Patients with only a single outpatient visit and those who did not undergo adequate diagnostic evaluation to determine the cause of IgE elevation were excluded. A total of 643 patients who completed comprehensive clinical, laboratory, and diagnostic assessments were included in the final analysis. Etiological causes of IgE elevation were classified based on clinical and laboratory findings. Results: The mean age of the 643 patients was 47.55±17.00 years, and 52.9% were female. The median serum total IgE level was 1520 (1001–62,753) IU/ml. Atopic diseases were identified as the most common etiological factor (n:530, 82.4%). Other causes included infectious diseases (5.3%), inflammatory diseases (1.2%), neoplasms (0.5%), primary immunodeficiency disorders (0.2%), drug-related causes (0.2%), and other conditions (0.2%). Despite comprehensive evaluation, no underlying cause could be identified in 65 patients (10.1%), who were classified as having idiopathic total IgE elevation. Conclusion: Although markedly elevated serum total IgE levels are predominantly associated with atopic diseases, a substantial proportion of patients have alternative or unidentified etiologies. A systematic and multidisciplinary diagnostic approach is essential to accurately identify the underlying cause of IgE elevation and to guide appropriate clinical management.
- Open Access
- 5 January 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 187 (4) , 385-391
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation
Introduction: Benralizumab, an anti-IL-5 receptor monoclonal antibody, induces near-complete eosinophil depletion and has demonstrated significant clinical benefits in severe eosinophilic asthma (SEA). Real-world data remain essential for evaluating its effectiveness outside controlled trial settings. The aim of the study was to assess the clinical, laboratory, and functional outcomes of benralizumab over 32 weeks in a real-life cohort of SEA patients in Türkiye, following its recent national approval. Methods: This retrospective study included biologic-naïve adults with SEA who initiated benralizumab between November 2023 and February 2025 and completed at least six consecutive doses. Peripheral blood eosinophil count (PBEC), clinically significant exacerbations (CSEs), Asthma Control Test (ACT) scores, and spirometric parameters were evaluated at baseline and week 32. Patients were classified as responders (ACT ≥20 and no CSE) or nonresponders. Results: Twenty-four patients (66.7% female; mean age 50.9 ± 13.1 years) were included. Median PBEC decreased from 800 (230–2,200) to 0 (0–100) cells/µL (p < 0.001). Median annual CSE frequency declined by 67% (p < 0.001). ACT scores improved from 9 (5–24) to 22 (9–25) (p < 0.001). Mean forced expiratory volume in 1 s (FEV1) increased from 1,719 ± 768 mL to 2,165 ± 831 mL (p < 0.001), while forced vital capacity (FVC) showed significant improvement. Forced expiratory flow between 25% and 75% of the FVC (FEF25–75) exhibited a nonsignificant trend toward increase. Sixteen patients (66.7%) were classified as responders. Responders had higher baseline PBEC, FEV1, and FEF25–75 values. Benralizumab was well tolerated, with only two mild adverse events observed. Conclusion: Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice.
- 5 January 2026
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 187 (4) , 385-391
Open AccessReal-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation
Introduction: Benralizumab, an anti-IL-5 receptor monoclonal antibody, induces near-complete eosinophil depletion and has demonstrated significant clinical benefits in severe eosinophilic asthma (SEA). Real-world data remain essential for evaluating its effectiveness outside controlled trial settings. The aim of the study was to assess the clinical, laboratory, and functional outcomes of benralizumab over 32 weeks in a real-life cohort of SEA patients in Türkiye, following its recent national approval. Methods: This retrospective study included biologic-naïve adults with SEA who initiated benralizumab between November 2023 and February 2025 and completed at least six consecutive doses. Peripheral blood eosinophil count (PBEC), clinically significant exacerbations (CSEs), Asthma Control Test (ACT) scores, and spirometric parameters were evaluated at baseline and week 32. Patients were classified as responders (ACT ≥20 and no CSE) or nonresponders. Results: Twenty-four patients (66.7% female; mean age 50.9 ± 13.1 years) were included. Median PBEC decreased from 800 (230–2,200) to 0 (0–100) cells/µL (p < 0.001). Median annual CSE frequency declined by 67% (p < 0.001). ACT scores improved from 9 (5–24) to 22 (9–25) (p < 0.001). Mean forced expiratory volume in 1 s (FEV1) increased from 1,719 ± 768 mL to 2,165 ± 831 mL (p < 0.001), while forced vital capacity (FVC) showed significant improvement. Forced expiratory flow between 25% and 75% of the FVC (FEF25–75) exhibited a nonsignificant trend toward increase. Sixteen patients (66.7%) were classified as responders. Responders had higher baseline PBEC, FEV1, and FEF25–75 values. Benralizumab was well tolerated, with only two mild adverse events observed. Conclusion: Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice.
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (Suppl_02) , 157-161
Severe asthma and disease heterogeneity in chronic rhinosinusitis with nasal polyps
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (Suppl_02) , 157-161
Severe asthma and disease heterogeneity in chronic rhinosinusitis with nasal polyps
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (03) , 259-264
Analysis of patients with severe asthma treated with add-on biologic agents
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (03) , 259-264
Analysis of patients with severe asthma treated with add-on biologic agents
- 23 December 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (4) , 286-298
Evaluation and differential diagnosis of eosinophilia: A tertiary allergy center experience
Eosinophilia is a hematologic finding that may indicate a wide range of underlying conditions, from common allergic diseases to rare and potentially life-threatening disorders such as hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and systemic mastocytosis. A structured diagnostic approach is crucial to identify the underlying etiology and guide appropriate treatment. This retrospective cross-sectional study evaluated 232 adult patients with peripheral blood absolute eosinophil counts ≥1000 cells/µL, who were referred to a tertiary immunology and allergy clinic between January 2018 and December 2022. Demographic, clinical, and laboratory data were analysed. Diagnoses were grouped according to eosinophil count severity: Mild (1000-1499 cells/µL), moderate (1500-4999 cells/µL), and severe (≥5000 cells/µL). Diagnoses were based on established international guidelines, supported by laboratory, radiological, immunological, and genetic investigations. The most commonly observed diagnoses included atopic diseases (53.4%), with allergic bronchopulmonary aspergillosis (ABPA, 11.6%), nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (6%), and chronic eosinophilic pneumonia (3%) occurring less frequently. Rare conditions included EGPA (1.7%), HES (1.7%), parasitic infections (1.3%), systemic mastocytosis (0.4%), and Gleich syndrome (0.4%). Innate immune defect was detected in 0.4%. Molecular testing identified myeloid variant HES in four patients (FIP1L1-PDGFRA and PDGFRB mutations). The etiology remained undetermined in 19.8% of the patients. Atopic diseases were the most frequent diagnosis across all eosinophilia severity groups (38.3% vs. 14.2% vs. 0.8% p< 0.001 respectively). Atopic diseases are the most common cause of eosinophilia in adults, but clinicians must remain vigilant for less common but clinically significant diagnoses such as ABPA, HES, EGPA, and systemic mastocytosis. Managing eosinophilia effectively depends on a multidisciplinary strategy that incorporates algorithm-based decision-making to support accurate diagnosis.
- 23 December 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (4) , 286-298
Evaluation and differential diagnosis of eosinophilia: A tertiary allergy center experience
Eosinophilia is a hematologic finding that may indicate a wide range of underlying conditions, from common allergic diseases to rare and potentially life-threatening disorders such as hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and systemic mastocytosis. A structured diagnostic approach is crucial to identify the underlying etiology and guide appropriate treatment. This retrospective cross-sectional study evaluated 232 adult patients with peripheral blood absolute eosinophil counts ≥1000 cells/µL, who were referred to a tertiary immunology and allergy clinic between January 2018 and December 2022. Demographic, clinical, and laboratory data were analysed. Diagnoses were grouped according to eosinophil count severity: Mild (1000-1499 cells/µL), moderate (1500-4999 cells/µL), and severe (≥5000 cells/µL). Diagnoses were based on established international guidelines, supported by laboratory, radiological, immunological, and genetic investigations. The most commonly observed diagnoses included atopic diseases (53.4%), with allergic bronchopulmonary aspergillosis (ABPA, 11.6%), nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (6%), and chronic eosinophilic pneumonia (3%) occurring less frequently. Rare conditions included EGPA (1.7%), HES (1.7%), parasitic infections (1.3%), systemic mastocytosis (0.4%), and Gleich syndrome (0.4%). Innate immune defect was detected in 0.4%. Molecular testing identified myeloid variant HES in four patients (FIP1L1-PDGFRA and PDGFRB mutations). The etiology remained undetermined in 19.8% of the patients. Atopic diseases were the most frequent diagnosis across all eosinophilia severity groups (38.3% vs. 14.2% vs. 0.8% p< 0.001 respectively). Atopic diseases are the most common cause of eosinophilia in adults, but clinicians must remain vigilant for less common but clinically significant diagnoses such as ABPA, HES, EGPA, and systemic mastocytosis. Managing eosinophilia effectively depends on a multidisciplinary strategy that incorporates algorithm-based decision-making to support accurate diagnosis.
- 13 December 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (3) , 339-349
Identifying future risk factors of uncontrolled asthma control: the TAAR study perspective
Risk factors associated with asthma symptom control is crucial for disease management. This study aimed to determine the risk factors of patients with uncontrolled asthma and to examine the relationship with their geographical patterns. This cross-sectional study was conducted at 36 centers across Turkey. Future risk factors (FRFs) such as exposure to triggers/allergens and inadequate or poor inhalation technique etc were identified based on the Global Initiative for Asthma (GINA) guidelines. The associations between FRFs and demographic and clinical characteristics, geographical regions, and levels of asthma control were analyzed. The study included 2053 adult asthma patients.At least one FRF was identified in 1576(76.8%) patients. The most common FRFs were exposure to allergens/triggers (n:664; 32.3%), impaired asthma symptom control(n:540; 26.3%) and eosinophilia(n:526; 25.6%). Regarding regional differences, the most prevalent FRFs in the Marmara region were exposure to allergens/triggers and frequent use of short-acting beta-2 agonists (>3 boxes/year). In contrast, eosinophilia was more common in the Southeastern region, while inadequate or poor inhalation technique, non-compliance with treatment, and psychosocial or socioeconomic problems were more frequently observed in the Eastern Anatolia region. Asthma control was achieved in 79.5% of patients without any FRFs; however, this rate decreased significantly to 25% among patients with more than four FRFs. This study demonstrates that FRFs in asthma vary according to demographic and disease characteristics, as well as geographical distribution. An increased number of FRFs was associated with asthma control. However, an individualized approach remains essential for achieving optimal asthma management.
- 13 December 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (3) , 339-349
Identifying future risk factors of uncontrolled asthma control: the TAAR study perspective
Risk factors associated with asthma symptom control is crucial for disease management. This study aimed to determine the risk factors of patients with uncontrolled asthma and to examine the relationship with their geographical patterns. This cross-sectional study was conducted at 36 centers across Turkey. Future risk factors (FRFs) such as exposure to triggers/allergens and inadequate or poor inhalation technique etc were identified based on the Global Initiative for Asthma (GINA) guidelines. The associations between FRFs and demographic and clinical characteristics, geographical regions, and levels of asthma control were analyzed. The study included 2053 adult asthma patients.At least one FRF was identified in 1576(76.8%) patients. The most common FRFs were exposure to allergens/triggers (n:664; 32.3%), impaired asthma symptom control(n:540; 26.3%) and eosinophilia(n:526; 25.6%). Regarding regional differences, the most prevalent FRFs in the Marmara region were exposure to allergens/triggers and frequent use of short-acting beta-2 agonists (>3 boxes/year). In contrast, eosinophilia was more common in the Southeastern region, while inadequate or poor inhalation technique, non-compliance with treatment, and psychosocial or socioeconomic problems were more frequently observed in the Eastern Anatolia region. Asthma control was achieved in 79.5% of patients without any FRFs; however, this rate decreased significantly to 25% among patients with more than four FRFs. This study demonstrates that FRFs in asthma vary according to demographic and disease characteristics, as well as geographical distribution. An increased number of FRFs was associated with asthma control. However, an individualized approach remains essential for achieving optimal asthma management.